

AMENDMENTS TO THE CLAIMS:

Claims 6-10, and 16-23 are pending in the current application. Claims 6-10 and 16-20 have been restricted and are withdrawn from consideration, and claims 21-23 stand rejected. Applicant requests that Examiner enter amended claims 21-23. The amended claims contain no new matter. The current listing replaces all prior versions of the claims.

In The Claims:

1. - 5. (canceled)

6. (Withdrawn) A method of inhibiting the proliferation of malignant cells, comprising administering to the malignant cells a nucleic acid encoding an E-domain peptide agent.

7. (Withdrawn) The method of claim 6, wherein the E-domain peptide agent is selected from the group consisting of: a trout E-domain peptide, an E-domain peptide homolog, and an E-domain peptide fusion protein.

8. (Withdrawn) The method of claim 7, wherein the E-domain peptide is an E-domain peptide of a rainbow trout.

9. (Withdrawn) The method of claim 8, wherein the trout E-domain peptide is selected from the group consisting of: Ea-2 domain peptide (SEQ ID NO:2) and Ea-4 domain peptide (SEQ ID NO:4).

10. (Withdrawn) The method of claim 9, wherein the nucleic acid encoding the E-domain peptide is administered in a pharmaceutical composition.

11. – 15. (canceled)

16. (Withdrawn) A method for reducing the invasiveness of malignant cells, comprising administering to the malignant cells a nucleic acid encoding an E-domain peptide agent.

17. (Withdrawn) The method of claim 16, wherein the E-domain peptide agent is selected from

the group consisting of: a trout E-domain peptide, an E-domain peptide homolog, and an E-domain peptide fusion protein.

18. (Withdrawn) The method of claim 17, wherein the E-domain peptide is an E-domain peptide of a rainbow trout.

19. (Withdrawn) The method of claim 18, wherein the trout E-domain peptide is selected from the group consisting of: Ea-2 domain peptide (SEQ ID NO:2) and Ea-4 domain peptide (SEQ ID NO:4).

20. (Withdrawn) The method of claim 19, wherein the nucleic acid encoding the E-domain peptide is administered in a pharmaceutical composition.

21. (Currently Amended) A method of inhibiting proliferation of a malignant cell[s], comprising administering to the malignant cell at least one E-domain peptide agent, ~~wherein the E-domain peptide agent~~ is selected from the group consisting of: a trout Ea2 or Ea4 E-domain peptide, a trout Ea2 or Ea4 E-domain peptide homolog, and a trout Ea2 or Ea4 E-domain peptide fusion protein.

22. (Currently Amended) A method of reducing the invasiveness of malignant cells, comprising administering to the malignant cells an E-domain peptide agent, ~~wherein the E-domain peptide agent~~ is selected from the group consisting of: a trout Ea2 or Ea4 E-domain peptide, a trout Ea2 or Ea4 E-domain peptide homolog, and a trout Ea2 or Ea4 E-domain peptide fusion protein.

23. (Currently Amended). The method of claim 22, wherein the trout Ea2 or Ea4 E-domain peptide is ~~an E-domain peptide of a rainbow trout and~~ is selected from the group consisting of: an Ea-2 domain peptide (SEQ ID NO:2), and an Ea-4 domain peptide (SEQ ID NO:4), and wherein the trout Ea2 or Ea4 E-domain peptide is administered in a pharmaceutical composition.